Exai Bio

Exai Bio is an early-stage diagnostics company developing an RNA and AI-powered liquid biopsy platform for early cancer detection. Founded in 2020, the company has identified a novel class of biomarkers called orphan non-coding RNAs (oncRNAs), which are abundant in the blood of cancer patients but largely absent in healthy individuals. By applying machine learning to patterns of these oncRNAs, Exai aims to detect cancer at its earliest stages, predict tissue of origin, and monitor therapy response. The company is currently in the research and development phase, building a large biomarker catalog and validating its approach across multiple cancer types.

Next-generation liquid biopsy platform analyzing orphan non-coding RNAs (oncRNAs) from blood, combined with artificial intelligence and machine learning to detect cancer, predict tissue of origin, and monitor therapy response.

Exai operates in the highly competitive liquid biopsy space, competing directly with well-funded companies like Grail (Illumina) and Guardant Health that focus on cell-free DNA analysis. Its differentiation lies in its novel oncRNA biomarkers and AI analytics, but it must prove clinical superiority or complementarity to achieve market share.